Cleveland BioLabs is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant unmet medical need. The company’s programs are focused on the implementation of novel pharmacological approaches to control cell death. Its proprietary drug candidates act via unique mechanisms and targets to kill cancer and protect healthy cells. For more information, visit www.cbiolabs.com.